Interferon ?1 (Human Fibroblast Protein Moiety)
Demyelinating Disease
MidAmerica Neuroscience Research Foundation at Rowe Neurology Instituteprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Demyelinating Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Methotrexate MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Phase 4 | BB |
Pittsburgh Compound B Unlabelled Yale University | Phase 2 | B |
ER-176 Mayo Clinic | Phase 2 | CCC |
[ 18f]3f4ap Yale University | Phase 1 | CC |
mk-6240 Yale University | Phase 1 | CC |
Same molecule, other indications
Interferon ?1 (Human Fibroblast Protein Moiety) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →